<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2d5ebce0-9b8a-43cf-8228-71cc0647b414,g:30fb766d-5434-4e4b-966e-7944ba14e5cd,d:5ee0919a145f4f4dbc16d9e71846297d--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sppi-20220504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF80L2ZyYWc6MWU0NzBmZjA4MWVmNGExNWFhZGZlMTAyMDEwNTNkOWUvdGFibGU6YTVhOWYwNDRkYWFhNDk4OWJlYTcwNzNjNmNmY2U2ODgvdGFibGVyYW5nZTphNWE5ZjA0NGRhYWE0OTg5YmVhNzA3M2M2Y2ZjZTY4OF8yLTEtMS0xLTMzMzI5_0e96849c-8b8f-4603-9bbb-6505c4ca5a31">false</ix:nonNumeric><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF80L2ZyYWc6MWU0NzBmZjA4MWVmNGExNWFhZGZlMTAyMDEwNTNkOWUvdGFibGU6YTVhOWYwNDRkYWFhNDk4OWJlYTcwNzNjNmNmY2U2ODgvdGFibGVyYW5nZTphNWE5ZjA0NGRhYWE0OTg5YmVhNzA3M2M2Y2ZjZTY4OF8zLTEtMS0xLTMzMzI5_7801b590-3c07-457a-8549-09cdefc5e1dc">0000831547</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sppi-20220504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000831547</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ee0919a145f4f4dbc16d9e71846297d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjIy_0898e8cb-df7b-495f-9022-11cda9346bd9">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8yMzg_353c65de-96c6-4e5a-ac2f-f83dda5e2768">May 4, 2022</ix:nonNumeric> </span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjIz_daf0a0a3-040a-4ec5-9dee-e8da4a5fd423">SPECTRUM PHARMACEUTICALS INC</ix:nonNumeric> </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6Y2Q1YTMzYWYzYmJkNDBiZDkxYWQ5Mjk5NWQ0NDdlZGUvdGFibGVyYW5nZTpjZDVhMzNhZjNiYmQ0MGJkOTFhZDkyOTk1ZDQ0N2VkZV8wLTAtMS0xLTMzMzI5_3815ec00-a0e0-4b2b-98c6-4c0386d18023">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6Y2Q1YTMzYWYzYmJkNDBiZDkxYWQ5Mjk5NWQ0NDdlZGUvdGFibGVyYW5nZTpjZDVhMzNhZjNiYmQ0MGJkOTFhZDkyOTk1ZDQ0N2VkZV8wLTEtMS0xLTMzMzI5_d76daa9e-17e2-417a-98da-95832c4dbc4c">001-35006</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6Y2Q1YTMzYWYzYmJkNDBiZDkxYWQ5Mjk5NWQ0NDdlZGUvdGFibGVyYW5nZTpjZDVhMzNhZjNiYmQ0MGJkOTFhZDkyOTk1ZDQ0N2VkZV8wLTItMS0xLTMzMzI5_c7c50118-c7de-4cde-814e-617e8ddaee19">93-0979187</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction <br/>of incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission <br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer <br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6NGZlYjI5MzY0NTE3NDhmNGI1ZDkzZTQwNjk2MWUxZmUvdGFibGVyYW5nZTo0ZmViMjkzNjQ1MTc0OGY0YjVkOTNlNDA2OTYxZTFmZV8wLTAtMS0xLTMzMzI5_407544cc-923e-4f3d-a65c-01111f671678">11500 South Eastern Avenue</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6NGZlYjI5MzY0NTE3NDhmNGI1ZDkzZTQwNjk2MWUxZmUvdGFibGVyYW5nZTo0ZmViMjkzNjQ1MTc0OGY0YjVkOTNlNDA2OTYxZTFmZV8wLTEtMS0xLTMzMzI5_db97b99c-a22f-41ae-9c39-91dc622b2d51">Suite 220</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6NGZlYjI5MzY0NTE3NDhmNGI1ZDkzZTQwNjk2MWUxZmUvdGFibGVyYW5nZTo0ZmViMjkzNjQ1MTc0OGY0YjVkOTNlNDA2OTYxZTFmZV8wLTItMS0xLTMzMzI5_1bb3dc19-0461-4cd3-8ac9-ae1214068a6f">Henderson</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6NGZlYjI5MzY0NTE3NDhmNGI1ZDkzZTQwNjk2MWUxZmUvdGFibGVyYW5nZTo0ZmViMjkzNjQ1MTc0OGY0YjVkOTNlNDA2OTYxZTFmZV8wLTMtMS0xLTMzMzI5_268852d0-8f81-4d96-9319-17220976c867">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6NGZlYjI5MzY0NTE3NDhmNGI1ZDkzZTQwNjk2MWUxZmUvdGFibGVyYW5nZTo0ZmViMjkzNjQ1MTc0OGY0YjVkOTNlNDA2OTYxZTFmZV8wLTQtMS0xLTMzMzI5_9e633dbd-b205-4088-9144-ee8ace9b91e5">89052</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjI0_cd93f7ff-3f94-475b-b6a3-5fc3e3ff2eb9">702</ix:nonNumeric>) <ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjE3_384fb59e-25da-4022-bd17-ff7a4e38b78c">835-6300</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address if changed since last report.)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjI1_d8ed6c66-c750-4dc0-b6fc-1238b99c10cd">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjE4_f1b1e893-f1e0-418d-98f7-8c8e7753b34b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjE5_8be0f7c5-5813-4b6e-a141-2961a9deb5c5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjIw_65d56f1b-a06f-461e-a614-c4601b58e5e4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:6pt;margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6YTZhNGZhYzQyNjUzNGE5OWFmMDdmZDg5NGEzOGMzNjkvdGFibGVyYW5nZTphNmE0ZmFjNDI2NTM0YTk5YWYwN2ZkODk0YTM4YzM2OV8xLTAtMS0xLTMzMzI5_bad1557d-01f2-41e9-9a6d-850df630bce9">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6YTZhNGZhYzQyNjUzNGE5OWFmMDdmZDg5NGEzOGMzNjkvdGFibGVyYW5nZTphNmE0ZmFjNDI2NTM0YTk5YWYwN2ZkODk0YTM4YzM2OV8xLTEtMS0xLTMzMzI5_95bfe663-9b2d-464e-b754-6d90181113e7">SPPI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGFibGU6YTZhNGZhYzQyNjUzNGE5OWFmMDdmZDg5NGEzOGMzNjkvdGFibGVyYW5nZTphNmE0ZmFjNDI2NTM0YTk5YWYwN2ZkODk0YTM4YzM2OV8xLTItMS0xLTMzMzI5_61db3ea2-748f-4ead-82b0-eb59bd0764a3">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).   Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i610c974f454045c4bcfe0f9e9b5161cf_D20220504-20220504" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVlZTA5MTlhMTQ1ZjRmNGRiYzE2ZDllNzE4NDYyOTdkL3NlYzo1ZWUwOTE5YTE0NWY0ZjRkYmMxNmQ5ZTcxODQ2Mjk3ZF8xL2ZyYWc6NGJjMGQ5YWUwNDExNDc3MTg3YWI1ZmRjMTlmMmEwODUvdGV4dHJlZ2lvbjo0YmMwZDlhZTA0MTE0NzcxODdhYjVmZGMxOWYyYTA4NV8xNjIx_ef63b836-2615-461d-8d9f-9a3deb65262c">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ee0919a145f4f4dbc16d9e71846297d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5.02&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:112%">Appointment of Director</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">On May 4, 2022, the Board of Directors (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:112%">Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221;) of Spectrum Pharmaceuticals, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:112%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221;) appointed Ms. Brittany K. Bradrick to serve as a member of the Board. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Ms. Bradrick has over 25 years of experience across investment banking, pharmaceuticals, and biotechnology sectors.  Since October 2021, Ms. Bradrick has served as Chief Financial Officer at Neurelis, Inc., a privately held neuroscience company created to address unmet needs of epilepsy and other rare central nervous system disorders. From June 2020 to February 2021, she served as Chief Financial Officer and from February 2021 to September 2021, she served as Chief Operating Officer and Chief Financial Officer at ViaCyte Inc., a private regenerative medicine company developing diabetes cell replacement therapies. In this role, she led the finance, legal, investor relations, business development and human resource functions. From September 2016 to May 2020, she served as Vice President, Strategy and Corporate Development at Insulet Corporation, a diabetes focused medical device company, where she headed global strategy, alliance management, competitive intelligence and venture investment functions.  From September 2010 to September 2016, Ms. Bradrick worked at Abbott Laboratories (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:112%">&#8220;Abbott&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">) as Director, Business Development and Alliance Management in diabetes care.  Prior to joining Abbott, Ms. Bradrick spent 10 years in investment banking for the life science industry with Piper Jaffray, Viant Capital, Credit Suisse and Chase Securities.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">There are no arrangements or understandings between Ms. Bradrick and any other persons pursuant to which she was elected to serve on the Board, and there are no transactions in which Ms. Bradrick has an interest requiring disclosure under Item 404(a) of Regulation S-K. The Board has determined that Ms. Bradrick is an independent director in accordance with the listing requirements of the Nasdaq Global Select Market.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Ms. Bradrick will serve an initial term of less than 60 days expiring at the Annual Meeting of Stockholders (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:112%">&#8220;Annual Meeting&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">) to be held on June 21, 2022. Additionally, the Board has nominated Ms. Bradrick for election to the Board at the Annual Meeting.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Ms. Bradrick shall receive fees, compensation and equity awards in accordance with the terms of the Company&#8217;s compensation policy for directors, which was described in the Company&#8217;s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2022, the terms of which are incorporated by reference herein. In connection with the appointment of Ms. Bradrick to the Board, she also is expected to enter into the Company&#8217;s standard form of indemnification agreement providing for indemnification and advancement of expenses, the form of which was filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 2, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The Company issued a press release regarding the appointment of Ms. Bradrick as a director of the Company which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:120%">Appointment of Interim Principal Financial Officer</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">On May 4, 2022, Thomas J. Riga was appointed to serve as the Company&#8217;s Interim Principal Financial Officer. Mr. Riga will continue to serve as the President and Chief Executive Officer of the Company, which position he has held since December 2021. There will be no change in Mr. Riga&#8217;s current compensation as President and Chief Executive Officer a result of his assumption of the additional role of Interim Principal Financial Officer.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Mr. Riga, 46, has served as the Company&#8217;s President and Chief Executive Officer since December 2021, as Chief Operating Officer since December 2017, as Executive Vice President, Chief Commercial Officer and Head of Business Development since May 2017 and as Senior Vice President and Chief Commercial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Officer since August 2014. From July 2013 to August 2014, he served as the Vice President, Corporate Accounts. Mr. Riga has over 20 years of pharmaceutical leadership experience. He has management experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen and Dendreon Pharmaceuticals, LLC. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma (black belt), manufacturing, and corporate accounts. Mr. Riga received his B.S. in Biology and Chemistry from St Lawrence University in Canton, New York, and is certified by UCLA&#8217;s Anderson School of Business as an accredited public company director.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The selection of Mr. Riga to serve as Interim Principal Financial Officer of the Company was not made pursuant to any arrangement or understanding with any other person. There are no family relationships between Mr. Riga and any other director or executive officer of the Company and Mr. Riga does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%">Financial Statements and Exhibits.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:112%">(d)    Exhibits.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">99.1       </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="sppispectrumpharma-brittan.htm">Press Release, dated Ma</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="sppispectrumpharma-brittan.htm">y 5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="sppispectrumpharma-brittan.htm">, 2022.</a></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">104        The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ee0919a145f4f4dbc16d9e71846297d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:137.25pt;padding-right:137.25pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">SPECTRUM PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">/s/ Keith M. McGahan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Keith M. McGahan <br/>Executive Vice President, Chief Legal Officer and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "sppi-20220504.htm", "description": "8-K", "secsgml_size_bytes": 41339}]
{"company-data": {"conformed-name": "SPECTRUM PHARMACEUTICALS INC", "cik": "0000831547", "assigned-sic": "2834", "irs-number": "930979187", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35006", "film-number": "22896367"}, "business-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052", "phone": "702-835-6300"}, "mail-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052"}, "former-company": [{"former-conformed-name": "NEOTHERAPEUTICS INC", "date-changed": "19960819"}, {"former-conformed-name": "AMERICUS FUNDING CORP", "date-changed": "19920703"}]}
sppi-20220504
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 4, 2022
SPECTRUM PHARMACEUTICALS INC
(Exact name of registrant as specified in its charter)
Delaware
001-35006
93-0979187
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
11500 South Eastern Avenue
Suite 220
Henderson
Nevada
89052
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
702
)
835-6300
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
SPPI
The NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Director
On May 4, 2022, the Board of Directors (the "
Board
") of Spectrum Pharmaceuticals, Inc. (the "
Company
") appointed Ms. Brittany K. Bradrick to serve as a member of the Board.
Ms. Bradrick has over 25 years of experience across investment banking, pharmaceuticals, and biotechnology sectors.  Since October 2021, Ms. Bradrick has served as Chief Financial Officer at Neurelis, Inc., a privately held neuroscience company created to address unmet needs of epilepsy and other rare central nervous system disorders. From June 2020 to February 2021, she served as Chief Financial Officer and from February 2021 to September 2021, she served as Chief Operating Officer and Chief Financial Officer at ViaCyte Inc., a private regenerative medicine company developing diabetes cell replacement therapies. In this role, she led the finance, legal, investor relations, business development and human resource functions. From September 2016 to May 2020, she served as Vice President, Strategy and Corporate Development at Insulet Corporation, a diabetes focused medical device company, where she headed global strategy, alliance management, competitive intelligence and venture investment functions.  From September 2010 to September 2016, Ms. Bradrick worked at Abbott Laboratories (
"Abbott"
) as Director, Business Development and Alliance Management in diabetes care.  Prior to joining Abbott, Ms. Bradrick spent 10 years in investment banking for the life science industry with Piper Jaffray, Viant Capital, Credit Suisse and Chase Securities.
There are no arrangements or understandings between Ms. Bradrick and any other persons pursuant to which she was elected to serve on the Board, and there are no transactions in which Ms. Bradrick has an interest requiring disclosure under Item 404(a) of Regulation S-K. The Board has determined that Ms. Bradrick is an independent director in accordance with the listing requirements of the Nasdaq Global Select Market.
Ms. Bradrick will serve an initial term of less than 60 days expiring at the Annual Meeting of Stockholders (the
"Annual Meeting"
) to be held on June 21, 2022. Additionally, the Board has nominated Ms. Bradrick for election to the Board at the Annual Meeting.
Ms. Bradrick shall receive fees, compensation and equity awards in accordance with the terms of the Company's compensation policy for directors, which was described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2022, the terms of which are incorporated by reference herein. In connection with the appointment of Ms. Bradrick to the Board, she also is expected to enter into the Company's standard form of indemnification agreement providing for indemnification and advancement of expenses, the form of which was filed as Exhibit 10.11 to the Company's Annual Report on Form 10-K, filed with the SEC on March 2, 2020.
The Company issued a press release regarding the appointment of Ms. Bradrick as a director of the Company which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Appointment of Interim Principal Financial Officer
On May 4, 2022, Thomas J. Riga was appointed to serve as the Company's Interim Principal Financial Officer. Mr. Riga will continue to serve as the President and Chief Executive Officer of the Company, which position he has held since December 2021. There will be no change in Mr. Riga's current compensation as President and Chief Executive Officer a result of his assumption of the additional role of Interim Principal Financial Officer.
Mr. Riga, 46, has served as the Company's President and Chief Executive Officer since December 2021, as Chief Operating Officer since December 2017, as Executive Vice President, Chief Commercial Officer and Head of Business Development since May 2017 and as Senior Vice President and Chief Commercial
Officer since August 2014. From July 2013 to August 2014, he served as the Vice President, Corporate Accounts. Mr. Riga has over 20 years of pharmaceutical leadership experience. He has management experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen and Dendreon Pharmaceuticals, LLC. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma (black belt), manufacturing, and corporate accounts. Mr. Riga received his B.S. in Biology and Chemistry from St Lawrence University in Canton, New York, and is certified by UCLA's Anderson School of Business as an accredited public company director.
The selection of Mr. Riga to serve as Interim Principal Financial Officer of the Company was not made pursuant to any arrangement or understanding with any other person. There are no family relationships between Mr. Riga and any other director or executive officer of the Company and Mr. Riga does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.
Item 9.01
Financial Statements and Exhibits.
(d)    Exhibits.
99.1
Press Release, dated Ma
y 5
, 2022.
104        The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPECTRUM PHARMACEUTICALS, INC.
Date:
May 5, 2022
By:
/s/ Keith M. McGahan
Keith M. McGahan
Executive Vice President, Chief Legal Officer and Secretary